Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-588210 Vaccine in Malignant Pleural Mesothelioma
NCT02661659Phase 1Withdrawn
- Sponsor
- University of Chicago
- Start
- Jun 2016
- Primary completion
- Oct 2017
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of S-488210/S-488211 in malignant pleural mesothelioma (MPM) (2 arms), sponsored by University of Chicago. Primary endpoint: Cytotoxic T lymphocyte induction at 8 months. Planned start Jun 2016; status: withdrawn.
02
Drugs
S-488210/S-488211
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02661659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661659.